Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 clinical trial for Ab-01.12

Next Previous
Trial Profile

A Phase 1/2 clinical trial for Ab-01.12

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ab-01.12 (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Sponsors Abera Bioscience AB

Most Recent Events

  • 16 Oct 2024 According to an Abera Bioscience media release, majority of the funding will be used for activities at NorthX Biologics and their Innovation Hub for vaccine development, while a smaller portion will be allocated to personnel costs at Abera. The company must submit a start report and a final report as per Vinnova's regulations. The company must be able to demonstrate incurred costs according to the project plan, failing which Vinnova may demand repayment.
  • 16 Oct 2024 According to an Abera Bioscience media release, the company has been awarded a 1 million SEK grant from Vinnova to advance the development of its innovative pneumococcal vaccine, Ab-01.12, which is an important step closer to clinical Phase 1. The grant covers a maximum of 1 million SEK, with 800,000 SEK to be disbursed in 2024 and the remaining amount in 2025.
  • 05 Dec 2023 According to an Abera Bioscience media release, final toxicology study completed with positive results and all regulatory studies required to start the first clinical studies have now been completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top